Physician profile
Patrick John Walker
NPI 1689328023
$5,774.11
in general payments reported to CMS, 2019-2025
15 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.00 · 2023: $234 · 2024: $4,417 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,760 · Travel and Lodging: $2,094 · Consulting Fee: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,760.20 |
| Travel and Lodging | $2,093.91 |
| Consulting Fee | $875.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,729.49 | 2024-2025 | Vercise, General Dbs |
| Amneal Pharmaceuticals LLC | $1,352.47 | 2024 | Rytary |
| Medtronic, INC. | $1,138.12 | 2022-2025 | Percept Pc Brainsense, Sensight, Signia |
| Bayer Healthcare Pharmaceuticals INC. | $110.08 | 2023 | |
| Acadia Pharmaceuticals INC | $99.35 | 2024 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $55.25 | 2024-2025 | Ultomiris |
| Neurelis, INC. | $47.49 | 2024-2025 | Valtoco |
| Kyowa Kirin, INC. | $42.25 | 2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $35.60 | 2025 | Rexulti |
| Sk Life Science, INC. | $35.56 | 2025 | |
| Argenx US, INC. | $33.25 | 2023 | Vyvgart |
| Janssen Biotech, INC. | $26.40 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $24.46 | 2025 | Austedo Xr |
| Abbvie INC. | $24.28 | 2025 | |
| Eisai INC. | $20.06 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.